LEUPROLIDE
HER2 Mutation-Related Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)protein_peptidePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the HER2 Mutation-Related Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zanidatamab Haihua Yuan | Phase 2 | B |
arx788 Ambrx, Inc. | Phase 2 | B |
Trastuzumab Duocarmazine QuantumLeap Healthcare Collaborative | Phase 1 | CCC |
Evorpacept QuantumLeap Healthcare Collaborative | Phase 1 | CC |
Zoladex TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 | CC |
View all 10 →
Same molecule, other indications
LEUPROLIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →